DE69531499D1 - Liposomenzubereitungen zur behandlung von viruserkrankungen - Google Patents
Liposomenzubereitungen zur behandlung von viruserkrankungenInfo
- Publication number
- DE69531499D1 DE69531499D1 DE69531499T DE69531499T DE69531499D1 DE 69531499 D1 DE69531499 D1 DE 69531499D1 DE 69531499 T DE69531499 T DE 69531499T DE 69531499 T DE69531499 T DE 69531499T DE 69531499 D1 DE69531499 D1 DE 69531499D1
- Authority
- DE
- Germany
- Prior art keywords
- liposomes
- treatment
- formulations
- hiv
- antiviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31673594A | 1994-10-03 | 1994-10-03 | |
US316735 | 1994-10-03 | ||
PCT/CA1995/000561 WO1996010399A1 (en) | 1994-10-03 | 1995-10-03 | Liposome-formulations for treatment of viral diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69531499D1 true DE69531499D1 (de) | 2003-09-18 |
DE69531499T2 DE69531499T2 (de) | 2004-06-24 |
Family
ID=23230423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69531499T Expired - Fee Related DE69531499T2 (de) | 1994-10-03 | 1995-10-03 | Liposomenzubereitungen zur behandlung von viruserkrankungen |
Country Status (15)
Country | Link |
---|---|
US (1) | US5773027A (de) |
EP (1) | EP0784470B1 (de) |
JP (1) | JPH10506396A (de) |
CN (1) | CN1165480A (de) |
AT (1) | ATE246920T1 (de) |
AU (1) | AU714043B2 (de) |
BR (1) | BR9509217A (de) |
CA (1) | CA2201631C (de) |
DE (1) | DE69531499T2 (de) |
ES (1) | ES2204964T3 (de) |
MX (1) | MX9702435A (de) |
NO (1) | NO971494L (de) |
NZ (1) | NZ293216A (de) |
PT (1) | PT784470E (de) |
WO (1) | WO1996010399A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605437D0 (en) * | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
US6015576A (en) * | 1997-08-29 | 2000-01-18 | Bio-Sphere Technology, Inc. | Method for inducing a systemic immune response to an antigen |
US6207185B1 (en) | 1996-03-22 | 2001-03-27 | Bio-Sphere Technology | Method for inducing a systemic immune response to an HIV antigen |
US6117449A (en) * | 1996-03-22 | 2000-09-12 | Bio-Sphere Technology, Inc. | Method for inducing a systemic immune response to a hepatitis antigen |
CA2270600A1 (en) * | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
WO2003041681A2 (en) * | 2001-11-13 | 2003-05-22 | Celator Technologies, Inc. | Lipid carrier compositions with enhanced blood stability |
DE60222580T2 (de) * | 2001-11-13 | 2008-06-12 | Celator Pharmaceuticals, Inc. | Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung |
US20130085146A1 (en) * | 2003-01-14 | 2013-04-04 | Rodney J.Y. Ho | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
WO2004064731A2 (en) * | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
US8986731B2 (en) * | 2003-08-26 | 2015-03-24 | Biolitec Pharma Marketing Ltd | Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy |
US20050048109A1 (en) * | 2003-08-26 | 2005-03-03 | Ceramoptec Industries, Inc. | Non-polar photosensitizer formulations for photodynamic therapy |
CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
US20110160642A1 (en) * | 2007-11-15 | 2011-06-30 | Wolfgang Neuberger | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
US9040079B2 (en) * | 2007-11-19 | 2015-05-26 | Biolitec Pharma Marketing Ltd | Pegylated compounds for age-related macular degeneration |
DK177532B1 (en) * | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
CA2930505C (en) | 2013-12-20 | 2019-06-18 | F. Hoffman-La Roche Ag | Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells |
WO2015091953A1 (en) | 2013-12-20 | 2015-06-25 | Roche Diagnostics Gmbh | Use of compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising peg moieties for stabilization of a cell |
JP6302560B2 (ja) | 2013-12-20 | 2018-03-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法 |
RU2669773C1 (ru) * | 2017-05-30 | 2018-10-16 | Федеральное государственное бюджетное учреждение "3 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации | Способ определения модуля скорости неманеврирующей аэродинамической цели по выборкам измерений дальности |
EP4108251A1 (de) | 2021-06-22 | 2022-12-28 | Solmic Biotech GmbH | Griffithsin zur verwendung in einem verfahren zur vorbeugung oder behandlung von infektionen mit respiratorischen viren |
EP4306130A1 (de) | 2022-07-11 | 2024-01-17 | Solmic Biotech GmbH | Inhalierbare formulierung zur verwendung bei der behandlung von bakteriellen lungeninfektionen |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4416872A (en) * | 1982-03-17 | 1983-11-22 | The United States Of America As Represented By The Secretary Of The Army | Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates |
US5254539A (en) * | 1985-08-26 | 1993-10-19 | U.S. Government, Dept. Of Health And Human Services, C/O National Institutes Of Health | Method of treating HIV with 2',3'-dideoxyinosine |
IL86009A (en) * | 1987-04-10 | 1991-09-16 | Us Health | Liposome-encapsulated phosphorylated nucleosides for treatment of retroviral diseases |
US4997761A (en) * | 1987-10-06 | 1991-03-05 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
ZA902710B (en) * | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
-
1995
- 1995-10-03 US US08/538,457 patent/US5773027A/en not_active Expired - Lifetime
- 1995-10-03 ES ES95932599T patent/ES2204964T3/es not_active Expired - Lifetime
- 1995-10-03 CA CA002201631A patent/CA2201631C/en not_active Expired - Fee Related
- 1995-10-03 JP JP8511231A patent/JPH10506396A/ja not_active Ceased
- 1995-10-03 MX MX9702435A patent/MX9702435A/es not_active IP Right Cessation
- 1995-10-03 WO PCT/CA1995/000561 patent/WO1996010399A1/en active IP Right Grant
- 1995-10-03 AU AU35603/95A patent/AU714043B2/en not_active Ceased
- 1995-10-03 AT AT95932599T patent/ATE246920T1/de not_active IP Right Cessation
- 1995-10-03 DE DE69531499T patent/DE69531499T2/de not_active Expired - Fee Related
- 1995-10-03 BR BR9509217A patent/BR9509217A/pt not_active Application Discontinuation
- 1995-10-03 EP EP95932599A patent/EP0784470B1/de not_active Expired - Lifetime
- 1995-10-03 PT PT95932599T patent/PT784470E/pt unknown
- 1995-10-03 NZ NZ293216A patent/NZ293216A/xx unknown
- 1995-10-03 CN CN95196052A patent/CN1165480A/zh active Pending
-
1997
- 1997-04-02 NO NO971494A patent/NO971494L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ293216A (en) | 1999-03-29 |
EP0784470A1 (de) | 1997-07-23 |
MX9702435A (es) | 1997-06-28 |
CA2201631A1 (en) | 1996-04-11 |
AU3560395A (en) | 1996-04-26 |
NO971494L (no) | 1997-05-27 |
CN1165480A (zh) | 1997-11-19 |
NO971494D0 (no) | 1997-04-02 |
ES2204964T3 (es) | 2004-05-01 |
EP0784470B1 (de) | 2003-08-13 |
WO1996010399A1 (en) | 1996-04-11 |
BR9509217A (pt) | 1998-01-27 |
AU714043B2 (en) | 1999-12-16 |
CA2201631C (en) | 2004-05-04 |
ATE246920T1 (de) | 2003-08-15 |
DE69531499T2 (de) | 2004-06-24 |
US5773027A (en) | 1998-06-30 |
JPH10506396A (ja) | 1998-06-23 |
PT784470E (pt) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69531499D1 (de) | Liposomenzubereitungen zur behandlung von viruserkrankungen | |
DK0774959T3 (da) | Liposomalt indgivelsessystem for biologisk aktive midler | |
SE9703191L (sv) | Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom | |
DE60115029D1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
CA2258811A1 (en) | Formulation for use in the prevention of pathogen induced diseases including hiv and hsv | |
ES2150595T3 (es) | Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota. | |
CA2197319A1 (en) | Lipid analogs for treating viral infections | |
ATE152614T1 (de) | Mittel zur behandlung entzündeter gewebe | |
IL112667A0 (en) | 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them | |
DE69822496D1 (de) | Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen | |
ATE103804T1 (de) | Pharmazeutische praeparate. | |
GEP20022751B (en) | Aqueous Pharmaceutical Composition Comprising an Active Ingredient Which Is Highly Insoluble in Water | |
WO1994027584A3 (en) | Arylating medicaments | |
HUP9900945A2 (hu) | Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában | |
CA2091134A1 (en) | Therapeutic agent for threatened abortion | |
RU98111152A (ru) | Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза | |
IL106491A0 (en) | Anti viral preparations | |
HUP0100937A2 (hu) | Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen | |
Murphy | New antiretroviral drugs part I: PIs | |
DE69926633D1 (de) | Injizierbare arzneiformulierungen von partricin derivaten | |
Gilden et al. | Curcumin trial finds no activity | |
RU95102712A (ru) | Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе | |
Hannig et al. | Surfactant therapy after electroporation mediated muscle injury in vivo | |
Mairdan et al. | Efficacy of Liposomal Albendazole for the Treatment of E. multilocularis in Rats | |
ITMI951943A0 (it) | Apparecchiatura per l'inattivazione virale di hiv in emoderivati e per supporto a trattamenti terapeutici di affezioni virali da hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |